Replies to post #37176 on Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

The global sarcoidosis therapeutics market is expected to be driven by research undertaking and funding to control the rising prevalence of sarcoidosis. For instance, the National Institutes of Health (NIH) granted US$ 8.3 Mn to the University of Pittsburgh to explore the relationship between gene activation process, sarcoidosis disease progression, and lung bacteria. Other major trends in global sarcoidosis therapeutics include strategic alliances. Pharma companies are working together or with research organizations to develop medications for the treatment of sarcoidosis. In March 2015, THERAMetrics Holding AG signed collaboration and licensing agreement with Centurion Pharma to develop and commercialize Aviptadil for sarcoidosis. In December 2018, aTyr Pharma announced collaboration with Foundation for Sarcoidosis Research (FSR) for assistance in clinical trial site initiation and patient enrollment for pulmonary sarcoidosis. Institutions and organizations are spreading awareness about sarcoidosis among people. In the U.K., the British Lung Foundation (BLF) is creating awareness about the early diagnosis and therapeutics of sarcoidosis.

https://www.transparencymarketresearch.com/sarcoidosis-therapeutics-market.html
LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global sarcoidosis therapeutics market to have an incremental growth of $46 million during the forecast period [Global Sarcoidosis Therapeutics Market 2019-2023], according to their latest market research report. The growth momentum of the market is expected to accelerate in the year-over-year growth.

https://www.businesswire.com/news/home/20190104005221/en/Global-Sarcoidosis-Therapeutics-Market-2019-2023-Rising-Awareness-about-Sarcoidosis-to-Boost-Demand-Technavio

[ratna1]

Sarcoidosis is a crippling disease!
I recall you posted on it before including the staggering numbers in the world wide market for such a therapeuticum!
This trial is conducted at the University Klinikum of Freiburg which brought Aviptadil back on the map with their publication in the New England Journal of Medicine. They first tried to start this trial 3 years ago but had to abandon it on both safety concerns as well as lack of funding due to Covid 19.. how ironic..
Since ADVITA was founded by the same department before they sold it to RELIEF I wonder wether they use that income to fund the trial or wether RLF is funding it?